The implications of HIV for the anaesthetist and the intensivist

Anaesthesia

Volumn 55, Issue 4, 2000, Pages 344-354

  Avidan, M S ^a   Jones, N ^b   Pozniak, A L ^c  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Anaesthesia; General; Human immunodeficiency virus; ICU; Infection

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; OPIATE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANESTHESIST; BACTERIAL PNEUMONIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTENSIVE CARE UNIT; LYMPHOCYTE COUNT; MORTALITY; MULTIDRUG RESISTANCE; OBSTETRICS; OCCUPATIONAL EXPOSURE; PERIPHERAL NEUROPATHY; PROGNOSIS; RASH; REVIEW; RISK MANAGEMENT; SERODIAGNOSIS; SURGICAL RISK; T LYMPHOCYTE; VIRUS TRANSMISSION;

ANALGESIA; ANESTHESIA; ANTI-HIV AGENTS; DISEASE TRANSMISSION, PATIENT-TO-PROFESSIONAL; DRUG INTERACTIONS; HIV INFECTIONS; HUMANS; INTENSIVE CARE;

EID: 0034083686     PISSN: 00032409     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2044.2000.01265.x     Document Type: Review

References (87)

1. Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. New England Journal of Medicine 1981; 305: 1425-31.
2. World Health Organisation. The Current Global Situation of the HIV/AIDS Pandemic. Geneva: World Health Organisation, 1995.
3. Benn S, Rutledge R, Folks TJ, et al. Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire. Science 1985; 230: 949-51.
4. Barre-Sinoussi P. HIV as the cause of AIDS. Lancet 1996; 348: 31-5.
5. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995; 373: 117-22.
6. Ho DD, Neumann AU, Perelson AS, et al. Rapid turnover of plasma virions and CD4 lymphocytes in HIV1 infection. Nature 1995; 373: 123-6.
7. Ho DD. Viral counts count in HIV infection. Science 1996; 272: 1124-5.
8. Haynes BF, Pantaleo G, Fauci AS. Towards an understanding of the correlates of protective immunity to HIV infection. Science 1996; 271: 324-8.
9. Quinn TC. Global burden of the HIV pandemic. Lancet 1996; 348: 99-106.
10. McClelland DB, McMenamin JJ, Moores HM, Barbara JA. Reducing risks in blood transfusion: process and outcome. Transfusion Medicine 1996; 6: 1-10.
11. Mast S, Gerberding J. Factors predicting infectivity following needlestick exposure to HIV. An in vitro model. Clinical Researclt 1991; 39: 58A.
12. Buergler JM, Kim R, Thisted RA, et al. Risk of human immunodeficiency virus in surgeons, anesthesiologists, and medical students. Anesthesia and Analgesia 1992; 75: 118-24.
13. Greene ES, Berry AJ, Arnold WP, Jagger J. Percutaneous injuries in anesthesia personnel. Anesthesia and Analgesia 1996; 83: 273-8.
14. Maz S, Lyons G. Needlestick injuries in anaesthetists. Anaesthesia 1990; 45: 677-8.
15. Editorial. Occupational infection among anaesthetists. Lancet 1991; 336: 1103.
16. Harrison CA, Rogers DW, Rosen M. Blood contamination of anaesthetic and related staff. Anaesthesia 1990; 45: 831-3.
17. Dodds RD, Barker SG, Morgan NH, et al. Self protection in surgery: the use of double gloves. British Journal of Surgery 1990; 77: 219-20.
18. Henderson DK. HIV-1 in the health care setting. In: Mandell G, Bennett RJ, Dolin R, eds. Principles and Practice of Infectious Diseases, 4th edn. New York: Churchill-Livingstone, 1996; 2632-56.
19. Matta H, Thompson AM, Rainey JB. Does wearing two pairs of gloves protect operating theatre staff from skin contamination? British Medical Journal 1988; 297: 597-8.
20. Browne RA, Chernesky MA. Infectious diseases and the anaesthetist. Canadian Journal of Anaesthesia 1988; 35: 655-65.
21. Ben David B, Gaitini L. Compliance with gloving in anesthesia: an observational study of gloving practice at induction of general anesthesia. Journal of Clinical Anesthesia 1997; 9: 527-31.
22. Stevens CK, Mentis SW, Downs JB. The human immunodeficiency virus: knowledge and precautions among anesthesiology personnel. Journal of Clinical Anesthesia 1991; 3: 266-75.
23. Berry AJ, Isaacson IJ, Kane MA, et al. A multicentre study of the prevalence of hepatitis B viral serological markers in anaesthesia personnel. Anesthesia and Analgesia 1984; 63: 738-42.
24. Centres for Disease Control and Prevention. Recommendations for prevention of HIV transmission in health care settings. Morbidity and Mortality Weekly Report 1987; 36: 1S-12S.
25. Centres for Disease Control and Prevention Update. Universal precautions for preventions of transmission of human immunodeficiency virus, hepatitis B virus and other blood borne pathogens in health care settings. Morbidity and Mortality Weekly Report 1988; 37: 377-88.
26. Parlow JL. Blood contamination of drug syringes used in anaesthesia. Canadian Journal of Anaesthesia 1989; 36: S61-2.
27. Trepanier CA, Lessard MR, Brochu JG, et al. Risk of cross-infection related to the multiple use of disposable syringes. Canadian Journal of Anaesthesia 1990; 37: 156-9.
28. Vandernbrouke-Grauls CMJE, Teeuw KB, Ballemans R, et al. Bacterial and viral removal efficiency, heat and moisture exchange properties of four filtration devices. Journal of Hospital Infection 1995; 29: 45-56.
29. Cochs J, Casals P, Villalonga R, et al. Prevention of cross contamination, patient to anesthesia apparatus to patient, using filters. Revista Espanola Anestesiologia y Reanimacion 1994; 41: 322-7.
30. Phillips RA, Monaghan WP. Incidence of visible and occult blood on laryngoscope blades and handles. Journal of the American Association Nurse Anaesthetist 1997; 65: 241-6.
31. Haase AT. Lentiviruses: an overview. In: Mandell G, Bennett RJ, Dolin R, eds. Principles and Practice of Infectious Diseases, 4th edn. New York: Churchill-Livingstone, 1996; 1584-90.
32. Department of Health. Guidelines on Post-Exposure Prophylaxis for Health Care Workers Occupationally Exposed to HIV: London: Department of Health, 1997.
33. Floridia M, Bucciardini R, Ricciardulli D, et al. A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease. Journal of Acquired Immune Deficiency Syndrome 1999; 20: 11-19.
34. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. New England Journal of Medicine 1997; 337: 734-9.
35. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS 1998; 12: 279-84.
36. Li TS, Tubiana R, Katlama C, et al. Long lasting recovery in CD4 T cell function and viral load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet 1998; 351: 1682-6.
37. Gazzard B, Moyle G. Revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-16.
38. Ayers J, Howton MJ, Layon AJ. Postoperative complications in patients with human immunodeficiency virus disease. Clinical data and a literature review. Chest 1993; 103: 1800-7.
39. Kobayashi TL, Dick W. Perioperative complications in HIV-positive patients. Masui. Japanese Journal of Anesthesiology 1994; 43: 565-71.
40. Hughes SC, Daily PA, Landers D, et al. Parturients infected with the human immunodeficiency virus and regional anaesthesia. Anesthesiology 1995; 82: 32-7.
41. Markovic SN, Knight PR, Murasko DM. Inhibition of interferon stimulation of natural killer cell activity in mice anesthetised with halothane or isorflurane. Anesthesiology 1993; 78: 700-6.
42. Santacana E, Aliaga L, Villar-Landeira JM. Anesthetic considerations in patients with human immunodeficiency virus infection. Revista Espanola Anestesiologia y Reanimacion 1993; 40: 137-45.
43. Brown MC, Crede WB. Predictive ability of Acute Physiology and Chronic Health Evaluation II scoring applied to human immunodeficiency virus-positive patients. Critical Care Medicine 1995; 23: 848-53.
44. Rosen MJ, Clayton K, Schneider RF, et al. Intensive care of patients with HIV infection: utilization, critical illnesses, and outcomes. Pulmonary complications of HIV infection study group. American Journal of Respiratory and Critical Care Medicine 1997; 155: 67-71.
45. Thyrault M, Gachot B, Chastang C, et al. Septic shock in patients with the acquired immunodeficiency syndrome. Intensive Care Medicine 1997; 23: 1018-23.
46. Stansell JD, Osmond DH, Charlebonis E, et al. Predictors of Pnenmocystis carinii pneumonia in HIV-infected persons. Pulmonary complications of HIV infection study group. American Journal of Respiratory and Critical Care Medicine 1997; 155: 60-6.
47. Benson CA, Spear J, Hines D, et al. Combined APACHE II score and serum lactate dehydrogenase as predictors of in hospital mortality caused by first episode PCP in patients with acquired immunodeficiency syndrome. American Review of Respiratory Disease 1991; 144: 319-23.
48. Huang L, Stansell JD. AIDS and the lung. Medical Clinics of North America 1996; 80: 775-801.
49. Opravil M, Marincek B, Fuchs WA, et al. Shortcomings of chest radiography in detecting Pneumocystis carinii pneumonia. Journal of Acquired Immune Deficiency Syndromes 1994; 7: 39-45.
50. Moskivic E, Miller R, Pearson M. High resolution computed tomography of Pneumocystis carinii pneumonia in AIDS. Clinical Radiology 1990; 42: 239-43.
51. Orholm M, Lundgren JD, Nielsen TL, Iversen J. Indication for fiberoptic bronclioscopy in HIV-intected patients suspected for Pneumocystis carinii pneumonia. Danish Medical Bulletin 1990; 37: 86-9.
52. Bozzette SA, Sattler FR, Chiu J, et al. A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the Acquired Immunodeficiency Syndrome. California collaborative treatment group. New England Journal of Medicine 1990; 323: 1451-7.
53. Gregg RW, Friedman BC, Williams JF, et al. Continuous positive airway pressure by face mask in Pneumocystis carinii pneumonia. Critical Care Medicine 1990; 18: 21-4.
54. Gachot B, Clair B, Wolff M, et al. Continuous positive airway pressure by face mask or mechanical ventilation in patients with human immunodeficiency virus infection and severe Pneumocystis carinii pneumonia. Intensive Care Medicine 1992; 18: 155-9.
55. Kumar SD, Krieger BP. CD4 lymphocyte counts and mortality in AIDS patients requiring mechanical ventilator support due to Pneumocystis carinii pneumonia. Chest 1998; 113: 430-3.
56. Gallant JE, Ko AH. Cavitatory pulmonary lesions in patients infected with human immunodeficiency virus. Clinical Infectious Disease 1996; 22: 671-82.
57. Rosenberg SG. HIV-related disease. In: Rosenberg SG, ed. Anesthesia Secrets. Philadelphia: Hanley and Belfus, 1996; 356-63.
58. Gatell JM, Marrades R, el Ebiary M, Torres A. Severe pulmonary infections in AIDS patients. Seminars in Respiratory Infections 1996; 11: 119-28.
59. Miller R. HIV-associated respiratory disease. Lancet 1996; 348: 307-12.
60. Price RW. Neurologic complications of HIV infection. Lancet 1996; 348: 445-52.
61. Lipshultz SE. Dilated cardiomyopathy in HIV infected patients. New England Journal of Medicine 1998; 339: 1153-5.
62. Blanc P, Boussuges A, Souk AJ, et al. Echocardiography on HIV patients admitted to the ICU. Intensive Care Medicine 1997; 23: 1279-81.
63. Dittrich H, Chow L, Denaro F, Spector S. Human immunodeficiency virus, coxsackievirus and cardiomyopathy. Annals of Internal Medicine 1988; 108: 308-9.
64. Kaul S, Fishbein MC, Siegel RJ. Cardiac manifestations of acquired immunodeficiency syndrome: an update. American Heart Journal 1991; 122: 537-44.
65. Brinkman K, ter Hofstede HJ, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS 1998; 12: 1735-44.
66. Singer EJ, Zorilla C, Fahy-Chandon B, et al. Painful symptoms reported by ambulatory HIV-infected men in a longitudinal study. Pain 1993; 54: 15-19.
67. Dixon P, Higginson I. AIDS and cancer pain treated with slow release morphine. Postgraduate Medical Journal 1991; 67: S92-4.
68. Parente F, Cernuschi M, Antinori S, et al. Severe abdominal pain in patients with AIDS: frequency, clinical aspects, causes, and outcome. Scandanavian Journal of Gastroenterology 1994; 29: 511-15.
69. Rynes RI. Painful rheumatic syndromes associated with human immunodeficiency virus infection. Rheumatic Diseases Clinics of North America 1991; 17: 79-87.
70. Rietsema WJ. Fever, erythroderma, abdominal pain, and renal failure following initiation of indinavir therapy. Clinical Infectious Disease 1997; 25: 1268-9.
71. Hewitt DJ, McDonald M, Portenoy RK, et al. Pain syndromes and etiologies in ambulatory AIDS patients. Pain 1997; 70: 117-23.
72. O'Neill WM, Sherrard JS. Pain in human immunodeficiency virus disease: a review. Pain 1993; 54: 3-14.
73. McArthur JH. The reliability and validity of the subjective peripheral neuropathy screen. Journal of the Association of Nurses in AIDS Care 1998; 9: 84-94.
74. Penfold J, Clark AJ. Pain syndromes in HIV infection. Canadian Journal of Anaesthesia 1992; 39: 724-30.
75. Larue F, Fontaine A, Colleau SM. Underestimation and undertreatment of pain in HIV disease: multicentre study British Medical Journal 1997; 314: 23-8.
76. Lefkowitz M. Pain management for the AIDS patient. Journal of the Florida Medical Association 1996; 83: 701-4.
77. Breitbart W, Rosenfeld BD, Passik SD, et al. The undertreatment of pain in ambulatory AIDS patients. Pain 1996; 65: 243-9.
78. Anand A, Carmosino L, Glatt AE. Evaluation of recalcitrant pain in HIV-infected hospitalized patients. Journal of the Acquired Immune Deficiency Syndrome 1994; 7: 52-6.
79. Halpern S, Preston R. HIV infection in the parturient. International Anesthesiology Clinics 1994; 32: 11-30.
80. Newell ML, Thorne C. Pregnancy and HIV infection in Europe. Acta Paediatrica Supplement 1997; 421: 10-14.
81. Connor EM, Sperling RS, Gelber R. et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. New England Journal of Medicine 1994; 331: 1173-80.
82. Dattel BJ. Antiretroviral therapy during pregnancy -beyond AZT (ZDV). Obstetrics and Gynecology Clinics of North America 1997; 24: 645-57.
83. McIntosh K. Antiretroviral resistance and HIV vertical transmission. Acta Paediatrica Supplement 1997; 421: 29-32.
84. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of HIV-1. A meta-analysis of 15 prospective cohort studies. New England Journal of Medicine 1999; 340: 977-87.
85. Riley LE, Greene MF. Elective cesarean delivery to reduce the transmission of HIV. New England Journal of Medicine 1999; 340: 1032-3.
86. Boyle RK. Herpes simplex labialis after epidural or patenteral morphine: a randomised prospective trial in an Australian obstetric population. Anaesthesia and Intensive Care 1995; 23: 433-7.
87. Cohen OJ, Fauci AS. Transmission of multidrug-resistant human immunodeficiency virus - the wake-up call. New England Journal of Medicine 1998; 338: 341-3.